Are High Doses of Chromium Safe?

by | Oct 6, 2011

Using chromium to improve sugar control in type 2 diabetes

By Dr. Jonathan Wright on 08/16/2011 

Question: I am a Doctor of Acupuncture and Oriental Medicine in California. Over this past weekend, I have been reading Suzanne Somers’s book, Breakthrough, and read where Dr. Wright had recommended 5,000 to 6,000 micrograms of chromium per day for sugar cravings and then reduced to 1,000 micrograms daily after the sugar cravings have disappeared.
5,000 micrograms seems excessive, and after reading some information on chromium on the web, it has been confirmed that over 600 micrograms may cause kidney failure…
I would like to know how sure Dr. Wright is about his recommendation of 5,000 mcg of chromium a day until sugar cravings have disappeared and his research. I can’t imagine a doctor with his reputation making a recommendation that may harm many patients in the future. Did the book mean to say 500 to 600 micrograms, not five to six thousand?
Dr. Wright: Congratulations on “doing your homework” to find out about safe and unsafe quantities of any supplement, including chromium, whether it’s for personal use or to recommend as a health care practitioner! Unfortunately, not everyone does.
Just to be very clear: there is nutritional chromium, also called trivalent chromium, and industrial chromium, also called hexavalent chromium.
Hexavalent chromium is the industrial poison featured in the movie Erin Brokovitch. Maybe that’s what some of your sources were reporting on, perhaps not knowing the difference?
But regardless, I can understand your surprise at the dose recommended in the book, since it is much larger than what you might typically see, even from many natural health resources.
I was quite surprised myself a few years ago when Dr. Richard Anderson, M.D, one of the top experts on chromium in these United States, wrote that the upper limit of chromium safety is 70,000 micrograms. (Yes, that’s 70,000.) At that time, he also wrote that the Environmental Protection Agency shared this opinion.
As some readers know, even with “authoritative” information, I usually won’t recommend anything that might be even slightly hazardous to anyone else without trying it myself. So for six months, I took 40,000 micrograms of chromium (trivalent, of course) daily.
The chromium levels measured in my hair analysis quite unsurprisingly went very, very high, but none of my blood test screenings changed, except my HDL-cholesterol, which went up. I didn’t feel any worse or better.
Of course, even though it appeared to be very safe, I don’t recommend anyone else do this.
But research shows that 200 micrograms of chromium per day just isn’t enough to improve sugar and insulin control in type 2 diabetes–it takes 1,000 micrograms of chromium per day to do the job. Some people may not need more than 1,000 micrograms. But over the years, I’ve found that the quantities noted in your message (and in Suzanne Somers’ book) are safe, and offer the quickest results. Once that initial progress has been made, then the dose can be tapered down to 1,000 micrograms daily for maintenance.

 

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

11 + 5 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });